(NASDAQ: ACXP) Acurx Pharmaceuticals's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 13.28%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 18.17%.
Acurx Pharmaceuticals's earnings in 2025 is -$14,103,103.On average, 1 Wall Street analyst forecast ACXP's earnings for 2025 to be -$25,128,463, with the lowest ACXP earnings forecast at -$25,128,463, and the highest ACXP earnings forecast at -$25,128,463. On average, 1 Wall Street analyst forecast ACXP's earnings for 2026 to be -$32,843,341, with the lowest ACXP earnings forecast at -$32,843,341, and the highest ACXP earnings forecast at -$32,843,341.
In 2027, ACXP is forecast to generate -$34,386,317 in earnings, with the lowest earnings forecast at -$34,386,317 and the highest earnings forecast at -$34,386,317.